Mike Burgess named head of oncology discovery translational area at Roche
This article was originally published in Scrip
Roche has named Dr Mike Burgess head of the oncology discovery and translational area (DTA). The oncology DTA, which is one of five disease-focused organisations at Roche, is part of the pharma research and early development (pRED) organisation, which oversees research, and early- to late-stage development in oncology. Dr Burgess was most recently head of academic alliances (part of pRED Development). He joined Roche from Lilly in 2006 as clinical research and licensing liaison, oncology, for Roche Products. In May 2008, he became the European Head of Roche’s clinical research early development unit in its oncology franchise.
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”